Clinical trials: Percutaneous Coronary Revascularization
Coronary Artery Disease
Resolute Integrity US Extended Length Sub-Study(RI US XL)
Prospective, multi-center, non-randomized, single-arm, open-label study to assess the safety and efficacy of the Resolute Integrity Stent for the treatment of de novo lesions in native coronary arteries with a reference vessel…
- Trial name
- RI-US XL (NCT01913600)
- Testing
- Resolute Integrity Stent
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Medtronic Vascular
High-risk Percutaneous Coronary Intervention
Magenta Elevate™ EFS in High-Risk PCI Patients
The Elevate™ EFS study is designed to evaluate the safety and feasibility of the Magenta Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) System in patients undergoing non-emergent, high-risk percutaneous coronary…
- Trial name
- NCT05727059
- Testing
- The Elevate™ System
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Magenta Medical Ltd.
Coronary Artery Disease, Coronary Disease
Sapphire 3 CTO Study
A prospective, open label, multi-center, single arm, observational study designed to evaluate the acute safety and device performance of the Sapphire 3 0.85, 1.0 and 1.25mm diameter coronary dilatation catheter in predilatation…
- Conditions
- Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases
- Trial name
- NCT06358508
- Testing
- Sapphire 3 Coronary Dilatation Catheter
- Where
- 14 sites in United States, Spain
- Volunteers
- 170 people
- Sponsor
- OrbusNeich
Coronary Arteriosclerosis, Acute Coronary Syndromes
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a…
- Trial name
- NCT00097591
- Testing
- Prasugrel, Clopidogrel
- Where
- United States
- Volunteers
- 13,619 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease
Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting
The purpose of this study is to provide information of the relative potency of prasugrel and clopidogrel on platelet function studies, inflammation, and myocyte necrosis in subjects undergoing elective percutaneous coronary…
- Trial name
- PRINCIPLE (NCT00357968)
- Testing
- Prasugrel, Clopidogrel
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 201 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Stenosis
Kidney Damage In Patients With Severe Fall In eGFR
This is a pilot study using a randomized, double blinded, comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI).
- Trial name
- NCT01136915
- Testing
- Iopamidol 370, Iodixanol 320
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Bracco Diagnostics, Inc
Coronary Disease
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)
The purpose of this study is to evaluate the safety and effectiveness of the investigational stent CoStar™ Paclitaxel-Eluting Coronary Stent- a reservoir based DES system in comparison to a surface coated DES stent (TAXUS™…
- Trial name
- NCT00165035
- Testing
- CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
- Where
- 2 sites in United States
- Volunteers
- 1,701 people
- Sponsor
- Cordis US Corp.
Acute Coronary Syndrome
A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome
The study will compare the safety and efficacy of prasugrel, administered at different doses with clopidogrel in the treatment of Asian participants with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.
- Trial name
- NCT00830960
- Testing
- Prasugrel, Clopidogrel
- Where
- 19 sites in China, South Korea and 2 more
- Volunteers
- 720 people
- Sponsor
- Eli Lilly and Company
Atrial Fibrillation
Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
There are insufficient data on the safety and efficacy of edoxaban plus antiplatelet therapy in subjects with atrial fibrillation (AF) following percutaneous intervention (PCI) with stenting.
- Trial name
- ENTRUST-AF-PCI (NCT02866175)
- Testing
- Edoxaban, Clopidogrel, Prasugrel
- Where
- 200 sites in Austria, Belgium and 16 more
- Volunteers
- 1,506 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Coronary Artery Disease
FAME II-10-year Follow-Up
The FAME-II trial was a prospective, multicenter, multinational, multi-continental, randomized clinical trial with an 'all comers' design.
- Trial name
- FAME2-10yFU (NCT06159231)
- Where
- 16 sites in United States, Belgium and 9 more
- Volunteers
- 888 people
- Sponsor
- CoreAalst BV
Coronary Artery Disease
Observational Study of OCT in a Patients Undergoing FFR
The purpose of this study is to define and evaluate optical coherence tomography (OCT) stent guidance parameters through prospective data collection in percutaneous coronary intervention (PCI) procedures of de novo lesions.
- Trial name
- ILUMIEN I (NCT01663896)
- Testing
- OCT stent guidance
- Where
- 36 sites in United States, Australia and 12 more
- Volunteers
- 418 people
- Sponsor
- Abbott Medical Devices
Angina Pectoris, Angina, Unstable
SPECTACL: SPECTroscopic Assessment of Coronary Lipid
The purpose of this study is to evaluate a near-infrared (NIR) spectroscopy system that has been designed to identify the chemical composition of coronary artery plaques in patients undergoing a percutaneous coronary intervention…
- Conditions
- Angina Pectoris, Angina, Unstable, Myocardial Infarction
- Trial name
- SPECTACL (NCT00330928)
- Testing
- Near Infrared Spectroscopy (NIRS) Imaging, intravascular ultrasound (IVUS)
- Where
- 6 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Infraredx
Coronary Artery Disease, Coronary Stenosis
ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)
The objective of this prospective, single-blind clinical investigation is to demonstrate the superiority of an Optical Coherence Tomography (OCT)-guided stent implantation strategy as compared to an angiography-guided stent…
- Conditions
- Coronary Artery Disease, Coronary Stenosis, Atherosclerosis, STEMI
- Trial name
- NCT03507777
- Testing
- Coronary PCI guided by OCT, Coronary PCI guided by Angiography
- Where
- 90 sites in United States, Australia and 18 more
- Volunteers
- 2,487 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Safe Surveillance of PCI Under Mechanical Circulatory Support With the Saranas Early Bird Bleed Monitoring System
The objective of this study is to establish the safety of complex high-risk Percutaneous Coronary Intervention (PCI) using Mechanical Circulatory Support (MCS) and surveillance with the Saranas Early Bird Bleed Monitoring System…
- Trial name
- SAFE-MCS (NCT05077657)
- Testing
- Early Bird® Bleed Monitoring System, Impella®
- Where
- 11 sites in United States
- Volunteers
- 203 people
- Sponsor
- Saranas, Inc.
Heart Failure
Protected PCI Study
A Prospective, multi-center, single-arm post-approval study of the IMPELLA® 2.5 System in Non Emergent High Risk PCI patients.
- Trial name
- NCT02831881
- Where
- United States
- Volunteers
- 369 people
- Sponsor
- Abiomed Inc.
Coronary Heart Disease
A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention
Study of SB-681323 (a novel p38 MAPkinase inhibitor) in subjects with documented coronary heart disease (CHD) undergoing elective percutaneous coronary intervention (PCI).
- Trial name
- NCT00291902
- Testing
- SB-681323
- Where
- 7 sites in Denmark, Poland
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Percutaneous Coronary Intervention
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
To test whether FFRangio-guided treatment is non-inferior to conventional pressure wire-guided treatment in patients with coronary artery disease.
- Trial name
- ALL-RISE (NCT05893498)
- Testing
- FFRangio, FFR or NHPR
- Where
- 59 sites in United States, Israel and 3 more
- Volunteers
- 1,924 people
- Sponsor
- CathWorks Ltd.
Percutaneous Coronary Intervention
A Clinical Trial Evaluating the Pan-vascular Interventional Robotic System for Panvascularization Interventional Surgery
The purpose of this prospective, randomized, open, parallel controlled, multicenter trial is to investigate the efficacy and safety of the pan-vascular interventional robotic system for percutaneous coronary intervention (PCI).
- Trial name
- NCT06502938
- Testing
- Pan-vascular interventional robotic system, Traditional artificial percutaneous coronary intervention
- Where
- 5 sites in China
- Volunteers
- 159 people
- Sponsor
- Shenzhen Institute of Advanced Biomedical Robot Co., Ltd.
Acute Coronary Syndromes
A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction
The purpose of this trial is to investigate the potential benefits/risks regarding pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants with elevated troponin scheduled for coronary…
- Trial name
- ACCOAST (NCT01015287)
- Testing
- Prasugrel
- Where
- 153 sites in Austria, Belgium and 17 more
- Volunteers
- 4,033 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease
Prospective multicEntric NonranDomized Registry
The purpose of this study is to evaluate the safety and efficacy of the eucaLimus Sirolimus Eluting stent system in patients with de novo coronary lesions.
- Trial name
- ExPEND (NCT02496169)
- Testing
- eucaLimus
- Volunteers
- 400 people
- Sponsor
- Eucatech AG